Name | Target | Clinical use |
---|---|---|
Adenosine receptor agonists | ||
GR79236 | Highly potent and selective adenosine A1 receptor agonist [12] | Ischemic heart disease [3, 25], sleep apnea [5], modulation of lipolysis and insulin sensitivity [18] |
GR79236X | Selective adenosine A1 receptor agonist [6] | |
GR190178 | Low efficacy (partial) adenosine A1 receptor agonist [13] | Cluster headache [13] |
CGS21680 | Selective adenosine A2A receptor agonist [6] | Huntington’s disease [7], spinal cord injury [36], bone regeneration [33] and overactive bladder [47] |
2-CI-IB-MECA | Selective adenosine A3 receptor agonist [6] | Atrial function [49], damage of the optic nerve and white matter ischemic damage [14] |
Adenosine receptor antagonists | ||
Caffeine | Non-selective adenosine A1 and A2A antagonist [34] | Treatment of headache, pain, apnea in premature children and neurodegenerative diseases [10] |
DPCPX | Depression [42], cancer [8, 30, 50] and neuroprotection [37] | |
SCH58261 | Potent and highly selective A2A receptor antagonist [15] | Spinal cord injury [36], epilepsy [29] and preeclampsia [40] |
JNJ-41942914, JNJ-39928122, JNJ-40529749, JNJ-40064440, and JNJ-41501798 | A2A receptor antagonists [16] | None |